Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.56 |
| ▸ | KLK7 | P49862 | 11/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 9/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.42 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.42 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752349 | 0.90 | BCHE (0.65) | BCHEKLK7KLK5 | |
| SCHEMBL21574397 | 0.90 | BCHE (0.65) | BCHEKLK7KLK5 | |
| SCHEMBL17104794 | 0.83 | BCHE (0.58) | BCHEKLK7KLK5 | |
| SCHEMBL12258542 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 | |
| SCHEMBL16403009 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 | |
| SCHEMBL12902908 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 | |
| SCHEMBL2392192 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 | |
| SCHEMBL21258139 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 | |
| SCHEMBL12258553 | 0.81 | BCHE (0.56) | BCHEKLK7KLK5 | |
| SCHEMBL2399000 | 0.81 | BCHE (0.60) | BCHEKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406140-B2 | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having AMPK activation effect | SHIONOGI & CO., LTD. (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190183866-A1 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183866-A1 | 5-SUBSTITUTED BENZIMIDAZOLE AND 5-SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE BOTH HAVING AMPK ACTIVATION EFFECT | PRKAG2, PRKAB2, PRKAG1 | BCHE 3233/4885KLK7 4094/4885KLK5 3671/4885 |
| US-10406140-B2 | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having AMPK activation effect | PRKAG2, PRKAB2, PRKAG1 | BCHE 3233/4885KLK7 4094/4885KLK5 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.